encountered, and metastasis from intracranial lesions is mostly thought to result from previous intracranial glioblastoma via the cerebrospinal fluid (CSF) seeding pathway.
Introduction
Glioblastoma is the most notorious intracranial tumor in adults, [1] and spinal cord glioblastoma is a rare entity with dismal outcome. [2] Anaplastic astrocytoma also pertains to aggressive behavior and the potential of malignant transformation into glioblastoma [1] with 23% 5-year survival rate. [3] Primary or secondary glioblastoma is diagnosed pending on the clinical course of preexisting, less-aggressive astrocytoma. [4] Through the improvement in imaging and treatment strategy, life expectancy has increased, and adequate local control of primary intracranial tumor has been achieved more commonly. Spinal glioblastoma is infrequently dura. The tumor is centrally located within the spinal cord, and we approached the tumor from the midline posteriorly. Spinal tumor biopsy of both thoracic and lumbar part was then performed, and the patient remained paraplegic with incontinence postoperatively. Spinal glioblastoma was the final diagnosis, and from both thoracic and the lumbar parts, showed typical features of glioblastoma inclusive of nuclear atypia, high mitotic index, necrosis and microvascular proliferation. IHC study showed positive glial fibrillary acidic protein (GFAP), high Ki-67 labeling index (30%), positive tumor protein p53 (TP53) mutation and negative finding of isocitrate dehydrogenase-1 (IDH-1), compared to the brain anaplastic astrocytoma [ Figures 2 and 3 ].
Aside from previous radiotherapy (5940 cGy/33 fractions) of the intracranial lesion, the patient then received radiotherapy over the spine (3750 cGy/15 fractions) and further chemotherapy, with the regimens of carboplatin, vincristine and bevacizumab.
Discussion
In the spinal cord tumors, astrocytoma accounts for 6-8%, and one-third of these tumors are high-grade. Spinal cord glioblastomas account for only 1-3% of all spinal cord tumors and 1-5% of all glioblastomas. [6] This may be explained by the nature of scarce proportion of neuroglia cells in the spinal cord. Otherwise, dismal outcome is also noted in spinal cord glioblastoma with mean survival from 6 to 18 months. [2] Glioblastoma, categorized by the clinical course, can be diagnosed as primary and secondary glioblastomas. The definition relies on whether preexisting, less-aggressive astrocytoma is present. Through improvement and understanding on a molecular basis, TP53, epidermal growth factor receptor (EGFR), phosphatase tensin homolog, and the marker of IDH-1, there are still limitations in differentiating primary or secondary glioblastoma. [4] For our patient, according to his history of previous cerebellar anaplastic astrocytoma and subsequent spinal cord glioblastoma, secondary glioblastoma was impressed. Followed up brain MRI, 1-year later post-CCRT showed cerebellar tumor shrinkage but with leptomeningeal enhancement [ Figure 1b ]. IHC study of anaplastic astrocytoma showed positive GFAP, EGFR, and p53 with negative expression of IDH-1; and the same finding for spinal glioblastoma except for Ki-67 expression [ Figures 2 and 3] . Otherwise, there was no significant difference of the IHC staining between the lumbar and thoracic glioblastoma. This finding implies that cerebellar anaplastic astrocytoma and spinal glioblastoma arise from the same origin with different proliferation potential, and secondary glioblastoma can be confirmed with assurance.
According to the literature, most secondary glioblastomas come from previous intracranial glioblastomas. Intracranial anaplastic astrocytoma with malignant transformation into glioblastoma is less frequent and mostly locally recurrent or along the white matter tract. Drop metastasis is a possible mechanism of secondary spinal glioblastoma through the CSF pathway. [5] For our patient with previous cerebellar anaplastic astrocytoma, the patient suffered subsquent spinal glioblastoma rather than in the intracranial region, which implies that one should not ignore the possibility of spinal lesion if the patient expresses contributory discomfort. Otherwise, since the progress of health care and treatment strategies, patient life expectancy has increased, and the possibility of spinal secondary glioblastoma increased, even though the primary intracranial lesion might not present as a glioblastoma. Early diagnosis and adequate management for 
Conclusions
We share a case of secondary glioblastoma from cerebellar anaplastic astrocytoma. Since the progress of treatment strategies and management, clinical physicians should not ignore the significance that secondary glioblastoma might ensue even in patients with lower grade gliomas.
